What is the recommended management for radioactive iodine‑refractory differentiated thyroid cancer?

Management of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Lenvatinib or sorafenib should be initiated as first-line systemic therapy for RAI-refractory DTC when disease progression is documented, with lenvatinib preferred based on superior progression-free survival benefit. 1, 2

Definition of RAI-Refractory Disease

RAI-refractory DTC is defined by any of the following criteria 1:

• Non-RAI-avid lesions on diagnostic imaging
• Loss of ability to concentrate RAI after initial therapy
• Disease progression despite RAI avidity on imaging

When to Initiate Systemic Therapy

Do not rush to start systemic therapy. Treatment should only begin when specific criteria are met 2:

• Documented progression by RECIST v1.1 (≥20% increase in sum of target lesions or new lesions appearing) 2
• Presence of symptoms from disease 2
• High tumor burden 2
• Lesions adjacent to vital structures 2

Maintain TSH suppression (<0.1 μIU/mL) in all patients with persistent structural disease while monitoring, unless specific contraindications exist 1

First-Line Systemic Therapy Options

Standard Multi-Kinase Inhibitors

Lenvatinib is the preferred first-line agent based on superior efficacy 1, 2:

• Median PFS: 18.3 months vs 3.6 months with placebo (HR 0.21; 99% CI 0.14-0.31; P<0.001) 2
• Absolute PFS gain of 14.7 months 2
• ESMO-MCBS score: 3 (meaningful clinical benefit) 1, 2
• Critical caveat: Treatment-related mortality rate >2% in pivotal SELECT trial 2

Sorafenib is an alternative first-line option 1:

• ESMO-MCBS score: 2 (lower than lenvatinib) 1
• May be considered when lenvatinib is contraindicated or not tolerated

Molecular-Targeted Therapy (Precision Medicine Approach)

Consider genetic testing with next-generation sequencing before initiating therapy to identify actionable mutations 1

For RET fusion-positive DTC 1:

• Selpercatinib (FDA-approved in US for RAI-refractory RET fusion-positive DTC, regardless of prior MKI therapy; EMA-approved in Europe only after prior MKI failure)
• Pralsetinib (FDA-approved in US for patients ≥12 years requiring systemic therapy)
• Both agents: ESMO-MCBS score 3, ESCAT score I-B 1

For NTRK fusion-positive DTC 1:

• Larotrectinib for metastatic disease not amenable to surgery with no satisfactory alternatives
• Entrectinib for metastatic/unresectable disease progressing despite standard therapy (approved for patients ≥12 years)
• Response rate in thyroid cancer subset: 42.9% 1
• Both agents: ESMO-MCBS score 3, ESCAT score I-C 1

For BRAF V600E-positive DTC 1:

• Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily 1

Second-Line Therapy

Cabozantinib is the standard second-line option after progression on lenvatinib or sorafenib 1, 2:

• Median PFS: not reached vs 1.9 months with placebo (HR 0.22) 2
• ESMO-MCBS score: 2 1
• Level I, Grade A evidence 1

Locoregional Treatment Options

Consider locoregional therapies for oligometastatic or symptomatic disease before or alongside systemic therapy 1:

• Palliative surgery for single progressive lesions 1
• External beam radiation therapy (EBRT) 1
• Radiofrequency ablation (RFA) for solitary lung lesions or symptomatic lesions 1
• Metastasectomy may be considered for oligometastatic disease in patients with good performance status 1

For bone metastases 1:

• Bisphosphonates or denosumab (bone resorption inhibitors) alone or combined with locoregional treatments 1
• Limited evidence for RFA or cryotherapy for bone lesions 1

Redifferentiation Strategies

Redifferentiation therapy aims to restore RAI uptake using MAPK pathway inhibitors 3, 4:

• Short-term protocols (10 days) appear as effective as longer durations (3-6 weeks), reducing toxicity and cost 3
• Trametinib plus dabrafenib for BRAF-mutated disease 3
• Trametinib alone for BRAF wild-type disease 3
• Iodine uptake restoration rates: 33-95% across studies 4
• Tumor response rates: 11-80% 4

Critical limitation: Randomized controlled trials are lacking; current evidence from prospective trials and case reports shows substantial variability in protocols 4

Critical Decision-Making Algorithm

1. Confirm RAI-refractory status (non-avid lesions, loss of uptake, or progression despite avidity) 1
2. Document progression by RECIST v1.1 or identify symptoms/high burden/vital structure involvement 2
3. Obtain molecular testing (NGS preferred) to identify actionable mutations 1
4. If actionable mutation present: Consider targeted therapy (selpercatinib/pralsetinib for RET, larotrectinib/entrectinib for NTRK, dabrafenib/trametinib for BRAF V600E) 1
5. If no actionable mutation or targeted therapy unavailable: Initiate lenvatinib as first-line (sorafenib if contraindicated) 1, 2
6. If progression on first-line MKI: Switch to cabozantinib 1, 2
7. Consider redifferentiation in select cases with BRAF or RAS mutations before committing to indefinite MKI therapy 3, 4

Common Pitfalls

Avoid starting systemic therapy too early 2:

• MKIs have not demonstrated overall survival benefit 5
• Adverse effects can significantly worsen quality of life, which is often excellent before treatment 5
• Watchful waiting with TSH suppression is appropriate for non-progressive disease 1

The optimal sequence of MKIs and selective kinase inhibitors cannot be determined from current evidence; regulatory constraints often drive decision-making 1

Treatment decisions must involve careful discussion with patients about expected benefits versus risks, as adverse events are frequent and can lead to dose reduction (40%) or discontinuation (4%) 1